Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1821-1829

  Yu, Guanzhen ^a   Wang, Jiejun ^a   Chen, Ying ^b   Wang, Xi ^a   Pan, Jun ^a   Li, Gang ^c   Jia, Zhiliang ^d   Li, Qiang ^d   Yao, James C ^d   Xie, Keping ^d,e  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PHOSPHORYLATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASES; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63549108509     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2138     Document Type: Article

References (48)

1. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002;5:5-11.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol 1998;11:870-7.
4. Yao JC,Tseng JF,Worah S, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 2005;23:3094-103.
5. Orsenigo E, Carlucci M, Braga M, et al. Prognostic factors of gastric neoplasms: experience with 1,074 cases undergoing surgical treatment at a single center. Tumori 2005;4:S86-7.
6. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. EurJ Cancer 2001;37:S9-15.
7. Peng Z, Wei D, Wang L, et al. RUNX3 inhibits the expression of vascular endothelial growth factor and reduced the angiogenesis, growth and metastasis of human gastric cancer. Clin Cancer Res 2006;12:6386-94.
8. McCulloch P,TaggartT, Ochiai A, O'Dowd G, Nash J, Sasako M. c-erbB2 and p53 expression arenot associated with stage progression of gastric cancer in Britain orJapan. EurJSurg Oncol 1997;23:304-9.
9. Bianco R, Melisi D, Ciardiello F,Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. EurJ Cancer 2006;42:290-4.
10. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005;5:171-93.
11. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
12. Sahin F, Kannangai R, Adegbola O,Wang J, Su G, Torbenson M. mTOR and p70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5.
13. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-52.
14. Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 2002;21:1800-11.
15. Bose S, Chandran S, Mirocha JM, Bose N. TheAkt pathwayin human breast cancer: a tissue-array-based analysis. Mod Pathol 2006;19:238-45.
16. LangSA,GaumannA,KoehlGE,etal.Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. IntJCancer 2007;120:1803-10.
17. XieK, Wei D, ShiQ,Huang S. Constitutive and in-ducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004;15:297-324.
18. Saito H, Osaki T, Murakami D, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg 2006;76:458-61.
19. Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 2003;37:28-33.
20. TanigawaN,AmayaH,MatsumuraM,Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15:826-32.
21. Nikiteas NI,Tzanakis N,Theodoropoulos G, et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 2007;10:12-7.
22. Maeda K, ChungYS, OgawaY, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer1996;77:858-63.
23. Minato E, Miki C,Tanaka K, et al.Vascular endothe-lial growth factor as an age-dependent prognostic factor in gastric cancer patients. Am J Surg 2002; 184:460-4.
24. Zheng H,Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006;26:3579-83.
25. Murakami D,Tsujitani S, Osaki T, et al. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacyofchemotherapy. Gastric Cancer 2007;10:45-51.
26. OzdemirF,AkdoganR,AydinF,etal.Theeffectsof VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res 2006;25:83-8.
27. Takiuchi H, Hirata I, Kawabe S, EgashiraY, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep2000;7:841-6.
28. Wan X, Shen N, MendozaA, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1 α/VEGF signaling. Neoplasia 2006;8:394-401.
29. Stephan S, Datta K,Wang E,et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004;10:6993-7000.
30. KwonYS, Hong HS, Kim JC, Shin JS, SonY. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005; 46:454-60.
31. Shimoyama S, Kaminishi M, JoujimaY, OoharaT, Hamada C,TeshigawaraW. Lymph node involvement correlation with survival in advanced gastric carcinoma: univariate and multi variate analyses. J Surg Oncol 1994;57:164-70.
32. Shiraishi N, Inomata M, Osawa N,Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2000;89:255-61.
33. Zheng L,Wang L, Ajani J, Xie K. Molecularbasis of gastric cancer development and progression. Gastric Cancer 2004;7:61-77.
34. YokotaT, Ishiyama S, SaitoT, et al. Lymph nodeme-tastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 2004;39:380-4.
35. YokotaT, Ishiyama S, SaitoT, et al. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res2002;22:3673-7.
36. Shun CT,Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-9.
37. Potrc S, Gadiijev E, HajdinjakT, Kavalar R. Clinico-pathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Hepatogas-troenterology 2007;54:308-14.
38. Victorzon M, Nordling S, Haglund C, LundinJ, Roberts PJ. Expression ofp53 protein as a prognostic factor in patients with gastric cancer. EurJ Cancer1996; 32A:215-20.
39. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007;98:726-33.
40. Kurozumi K, NishidaT, Nakao K, Nakahara M, Tsujimoto M. Expression ofCD44 variant 6 and lymphatic invasion: importance to lymph node metastasis ingastriccancer.WorldJSurg1998;22:853-7.
41. Pinto-de-Sousa J, David L, Almeida R, et al. cerbB-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002;10:247-56.
42. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. IntJ Oncol 2004;24:893-900.
43. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003;9:1421-6.
44. Del Bufalo D, Ciuffreda L,Trisciuoglio D,etal. Anti-angiogenic potential of the mammalian target of rapa-mycin inhibitor temsirolimus. Cancer Res 2006;66: 5549-54.
45. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22.
46. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent an-giogenesis and VEGF expression in multiple myeloma cells. Oncogene2007;26:2255-62.
47. Guan L, Song K, Pysz MA, et al. Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells. J Biol Chem 2007;282:14213-25.
48. Roux PP, Shahbazian D, Vu H, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007;282:14056-64.